These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28878690)

  • 1. Regulation of Pulmonary Vascular Smooth Muscle Contractility in Pulmonary Arterial Hypertension: Implications for Therapy.
    Lyle MA; Davis JP; Brozovich FV
    Front Physiol; 2017; 8():614. PubMed ID: 28878690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostaglandin and prostaglandin receptors: present and future promising therapeutic targets for pulmonary arterial hypertension.
    Zeng C; Liu J; Zheng X; Hu X; He Y
    Respir Res; 2023 Nov; 24(1):263. PubMed ID: 37915044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NMDA-Type Glutamate Receptor Activation Promotes Vascular Remodeling and Pulmonary Arterial Hypertension.
    Dumas SJ; Bru-Mercier G; Courboulin A; Quatredeniers M; Rücker-Martin C; Antigny F; Nakhleh MK; Ranchoux B; Gouadon E; Vinhas MC; Vocelle M; Raymond N; Dorfmüller P; Fadel E; Perros F; Humbert M; Cohen-Kaminsky S
    Circulation; 2018 May; 137(22):2371-2389. PubMed ID: 29444988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapies in pulmonary arterial hypertension.
    Montani D; Chaumais MC; Guignabert C; Günther S; Girerd B; Jaïs X; Algalarrondo V; Price LC; Savale L; Sitbon O; Simonneau G; Humbert M
    Pharmacol Ther; 2014 Feb; 141(2):172-91. PubMed ID: 24134901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current therapeutics and practical management strategies for pulmonary arterial hypertension.
    Agarwal R; Gomberg-Maitland M
    Am Heart J; 2011 Aug; 162(2):201-13. PubMed ID: 21835279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Update: Preclinical developments for the treatment of pulmonary arterial hypertension].
    Janssen W; Ghofrani HA; Weissmann N; Grimminger F; Schermuly RT
    Dtsch Med Wochenschr; 2009 Aug; 134 Suppl 5():S157-9. PubMed ID: 19718604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.
    Schermuly RT; Stasch JP; Pullamsetti SS; Middendorff R; Müller D; Schlüter KD; Dingendorf A; Hackemack S; Kolosionek E; Kaulen C; Dumitrascu R; Weissmann N; Mittendorf J; Klepetko W; Seeger W; Ghofrani HA; Grimminger F
    Eur Respir J; 2008 Oct; 32(4):881-91. PubMed ID: 18550612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension.
    Alencar AKN; Montes GC; Barreiro EJ; Sudo RT; Zapata-Sudo G
    Front Pharmacol; 2017; 8():858. PubMed ID: 29255415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?
    Koress C; Swan K; Kadowitz P
    Curr Hypertens Rep; 2016 Apr; 18(5):42. PubMed ID: 27118316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of smooth muscle cell hypoxia inducible factor-1α underlies increased vascular contractility in pulmonary hypertension.
    Barnes EA; Chen CH; Sedan O; Cornfield DN
    FASEB J; 2017 Feb; 31(2):650-662. PubMed ID: 27811062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rho-kinase inhibitors.
    Fukumoto Y; Shimokawa H
    Handb Exp Pharmacol; 2013; 218():351-63. PubMed ID: 24092347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble guanylate cyclase stimulators in pulmonary hypertension.
    Stasch JP; Evgenov OV
    Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crucial role of ROCK2 in vascular smooth muscle cells for hypoxia-induced pulmonary hypertension in mice.
    Shimizu T; Fukumoto Y; Tanaka S; Satoh K; Ikeda S; Shimokawa H
    Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2780-91. PubMed ID: 24135024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial nitric oxide synthase-enhancing G-protein coupled receptor antagonist inhibits pulmonary artery hypertension by endothelin-1-dependent and endothelin-1-independent pathways in a monocrotaline model.
    Liu CP; Dai ZK; Huang CH; Yeh JL; Wu BN; Wu JR; Chen IJ
    Kaohsiung J Med Sci; 2014 Jun; 30(6):267-78. PubMed ID: 24835346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy.
    Schermuly RT; Pullamsetti SS; Kwapiszewska G; Dumitrascu R; Tian X; Weissmann N; Ghofrani HA; Kaulen C; Dunkern T; Schudt C; Voswinckel R; Zhou J; Samidurai A; Klepetko W; Paddenberg R; Kummer W; Seeger W; Grimminger F
    Circulation; 2007 May; 115(17):2331-9. PubMed ID: 17438150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evidence-based approach to the management of pulmonary arterial hypertension.
    Archer SL; Michelakis ED
    Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Enhanced Ca2+-sensing receptor function in pulmonary hypertension].
    Yamamura A; Yamamura H; Yuan JX
    Yakugaku Zasshi; 2013; 133(12):1351-9. PubMed ID: 24292183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating pulmonary arterial hypertension: current treatments and future prospects.
    Raja SG; Raja SM
    Ther Adv Chronic Dis; 2011 Nov; 2(6):359-70. PubMed ID: 23251761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signal Mechanisms of Vascular Remodeling in the Development of Pulmonary Arterial Hypertension.
    Li MX; Jiang DQ; Wang Y; Chen QZ; Ma YJ; Yu SS; Wang Y
    J Cardiovasc Pharmacol; 2016 Feb; 67(2):182-90. PubMed ID: 26448276
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.